A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IAP / immunosuppressive acidic protein

[Related PubMed/MEDLINE]
Total Number of Papers: 199
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IAP  (>> Co-occurring Abbreviation)
Long Form:   immunosuppressive acidic protein
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 [Influence of perioperative leukodeplated red blood cell transfusion on immune function of patients with bladder cancer]. RBC
2017 [Clinical Evaluation of Immunosuppressive Acidic Protein in the Serum of Patients with Inflammatory Breast Recurrence]. QOL
2016 [Clinical Evaluation of Immunosuppressive Acidic Protein in the Serum of Patients with Locally Advanced Breast Cancer during Mohs Paste Treatment]. CRP, HPLC, KYN, QOL, Trp
2016 [Study of the Immunological Stress Caused by Breast Surgery Methods]. ---
2014 Depression in older patients with advanced colorectal cancer is closely connected with immunosuppressive acidic protein. CRC, NK, NLR, SDS
2013 Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK). OS, PSK, RFS, UFT
2011 Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: a pilot study. LEM, QOL
2010 [Immunosuppressive acidic protein (IAP)]. ---
2009 [Indoleamine 2,3-dioxygenase activity during chemotherapy in patients with breast cancer]. HPLC, IDO, KYN, Trp
10  2008 Cell transfer regimens in patients with highly advanced surgically unresectable non-small cell lung cancer: significantly improved overall survival in patients with lower levels of serum immunosuppressive acidic protein. NSCLC
11  2008 Prognostic role of immunosuppressive acidic protein in patients with esophageal cancer. ---
12  2008 Serum immunosuppressive acidic protein reflects systemic deterioration of colorectal cancer patient condition. ---
13  2008 [Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy]. HPLC, IDO, KYN, Trp
14  2007 Neutrophil elastase inhibitor (sivelestat) preserves antitumor immunity and reduces the inflammatory mediators associated with major surgery. IL-6
15  2007 Serum immunosuppressive acidic protein levels in patients with severe acute pancreatitis. JSS, SAP
16  2007 [Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers]. ---
17  2006 Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. NK, PSK
18  2006 Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome. CARS, Con, LAK
19  2006 Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy. ---
20  2006 [Chromophobe renal cell carcinoma: a clinicopathological study of 16 cases]. CRP, RCC
21  2005 Immunosuppressive acidic protein detects high nuclear grade localized renal cell carcinoma. RCC
22  2005 [Antitumor effects of intratumoral injection of Basidiomycetes preparations]. ---
23  2005 [Immunosuppressive acid protein (IAP)]. ---
24  2005 [Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer]. IDO
25  2004 Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor. PHA, PWM, SI
26  2004 [Life-prolonging effect of immunocell BAK (BRM activated killer) therapy--evidence based integrative medicine]. BAK, BRM, NIE, QOL
27  2004 [Study of indoleamine 2,3-dioxygenase expression in patients of esophageal squamous cell carcinoma]. IDO
28  2003 Allogenic blood transfusion is an independent risk factor for infective complications after less invasive gastrointestinal surgery. ---
29  2003 Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. BAK, BRM, CR, PR, QOL
30  2003 Prognostic value of preoperative serum immunosuppressive acidic protein in patients with esophageal squamous cell carcinoma. CRP
31  2003 Serum immunosuppressive acidic protein as an interleukin-6 related index of deteriorating condition in gastric cancer patients. IL-6
32  2003 Technetium-99 m sestamibi imaging in patients with subacute thyroiditis. SAT
33  2003 [Activation of antitumor immunity by intratumor injection of biological preparations]. BRMs
34  2002 Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer. CEA, IL-2R
35  2002 Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival. PHA, PSK, PWM
36  2002 [Change of immunosuppressive acidic protein in sera of patients with pulmonary tuberculosis and its clinical significance]. TB
37  2002 [Prognostic value of serum immunosuppressive acidic protein in renal cell carcinoma]. RCC, ROC
38  2001 Clinical study of testicular germ cell tumors. AFP, beta-hCG, LDH, NSGCTTs
39  2001 Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. i.p, i.v, LUAE, PS
40  2001 Serum immunosuppressive acidic protein as a potent prognostic factor for patients with metastatic renal cell carcinoma. ---
41  2000 Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. CEA, SCC
42  2000 Immunosuppressive acidic protein (IAP) level used to monitor adjuvant arthritis in rats. AA, CBP, Con A, MTX
43  2000 Predictive value of serum immunosuppressive acidic protein for lung metastasis after amputation of murine osteosarcoma of the lower limb. ---
44  1999 Circulating levels of soluble CD30 and other markers in colorectal cancer patients. IL-1ra, sCD30, sIL-2R, Th2
45  1999 Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. ---
46  1999 Perioperative allogenic blood transfusion and serum levels of immunosuppressive acidic protein in patients undergoing resection of colorectal carcinoma. ---
47  1999 Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients. IL
48  1999 Tumor-specific cytocidal and immunopotentiating effects of relatively low molecular weight products derived from the basidiomycete, Agaricus blazei Murill. LM, LM-3
49  1999 [Immunosuppressive acidic protein (IAP)]. ---
50  1999 [Investigation of serum immunosuppresive acidic protein levels in gynecological tumor]. ---
51  1998 Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice. ---
52  1998 Effects on host of modified PVP therapy combined with biological response modifiers in lung cancer. BRMs, QOL
53  1998 Immunosuppressive factors: role in cancer development and progression. IL-10, PGE2, SER, TGF-beta
54  1998 Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer. sTNF-RI
55  1998 The efficacy of immunochemotherapy with strontium (Sr) in the 1,2-dimethylhydrazine (DMH) induced rat carcinogenetic model: ultrastructural characteristics of the mitochondria in the liver. DMH, Sr
56  1998 The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. BAK, CAIE, PBMC, QOL
57  1997 Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients. NK
58  1997 Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer. sIL-2R
59  1997 Combination assay for tumor markers in oral squamous cell carcinoma. CEA, OSCC, SCCA
60  1997 Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. 5-FU, PS
61  1997 Predictive value of serum immunosuppressive acidic protein for staging renal cell carcinoma: comparison with other tumour markers. CRP, ESR, RCC, ROC
62  1997 Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases. ESR
63  1996 Acute-phase plasma proteins in gastric cancer: association with metastatic potential and prognosis. ACT, por
64  1996 Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy. LDCY
65  1996 Effect of surgical stress on immune function in patients with urologic cancer. Ig
66  1996 Immunosuppressive acidic protein (IAP) level in serum and peritoneal washings, and its implication in determining multidisciplinary treatments. ---
67  1996 Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. ---
68  1996 [A case of inflammatory pseudotumor of the lung with suppressed immune response in the patient with renal cell carcinoma after nephrectomy and administration of interferon]. IFN
69  1996 [Immunosuppressive acid protein in lung tuberculosis]. ESR
70  1996 [Measurement of the plasma transforming growth factor-beta 1 (TGF-beta 1) level in patients of gastric carcinoma--compared with the serum IAP level and the lymphocyte subsets (CD3, CD4, CD8)]. ELISA, TGF-beta1
71  1996 [Role of serum E-selectin (ELAM-1) and inflammatory parameters in patients with renal cell carcinoma]. CRP, ESR, RCC, SLeA
72  1996 [Significance of 5'-deoxy-5-fluorouridine (5'-DFUR) administration before surgery for advanced gastric and colonic cancers--activity of pyrimidine nucleoside phosphorylase (PyNPase) and serum immunosuppressive acidic protein (IAP)]. 5'-DFUR, PyNPase
73  1996 [The combination assay of tumor markers by multivariate analysis for improvements of the diagnostic precision in malignancies]. ALP, CA125, CAMPAS, TPA
74  1995 Case of leiomyomatosis peritonealis disseminata treated with a gn-rh analog. LPD
75  1995 Changes of white blood cells, immunosuppressive acidic protein, and interleukin-2 receptor after open heart surgery. sIL-2R
76  1995 Curative treatments of murine Colon26 solid tumors by immunochemotherapy with G-CSF and OK-432. BRMs
77  1995 Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. IDO, IFN-gamma, NPT, Trp
78  1995 Modulation of CD4 antigen expression on the lymphocyte surface by immunosuppressive acidic protein in cancer patients. PBLs
79  1995 Significance of increased neutrophils in patients with advanced colorectal cancer. ---
80  1994 Antitumor effect of intratumoral administration of biological response modifiers: induction of immunosuppressive acidic protein, a type of alpha 1-acid glycoprotein, in mice. BRMs, CR, IL-1, TNF
81  1994 Evaluation of immunosuppressive acidic protein in human ovarian cancer. ---
82  1994 Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer. OS, SCC
83  1994 Immunosuppressive acidic protein in intraocular fluids. ---
84  1994 Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels. ---
85  1994 Serum immunosuppressive acid protein predicts lymph node metastases in patients with renal cell carcinoma. ---
86  1994 Serum immunosuppressive acidic protein in haemodialysis patients with and without acquired cystic disease of the kidney. ACDK
87  1994 Serum level of immunosuppressive acidic protein in haemodialysis patients with or without renal cell carcinoma. ---
88  1994 Serum soluble interleukin-2 receptor in colorectal cancer. IL-2R
89  1994 Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer. alpha-FTP, CA19-9, CEA, IL-2R
90  1994 [Antitumor activity of monoclonal antibody MI2 against immunosuppressive acidic protein in vitro]. ---
91  1994 [Expression and significance of immunosuppressive acidic protein (IAP) in human esophageal squamous cell carcinoma]. ---
92  1994 [Prognostic factors in patients with stage 4B renal cell carcinoma following nephrectomy]. CRP, ESR, IFN
93  1993 Changes in serum immunosuppressive acidic protein following surgery in patients with renal carcinoma. ---
94  1993 Detection of serum cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-bearing mice. IL-3, IL-6, TGF-beta
95  1993 Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity. AFP, CA19-9, CEA, FER, SCC, SCCA
96  1993 Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. NK
97  1993 [Antitumor effect of PSK and its combined effect with CDDP on ovarian serous adenocarcinoma-bearing nude mice]. NK
98  1993 [Differences in antitumor effect of various BRMs by intratumoral administration: induction of immunosuppressive acidic protein]. BRM, CIAE
99  1993 [Preoperative grading of renal cell carcinoma by plasma immunosuppressive acidic protein level and tumor diameter using discriminant analysis]. ---
100  1993 [Utility of measurement of tumor markers for preoperative staging of gastric cancer]. AFP, CA125, CA19-9, CEA, s-BMG, SA, TPA